Immucell CORP /DE/ Form 4 insider transactions

Director Kathy V. Turner was granted 17,899 non-qualified stock options as compensation for board service.

Director David Scott Tomsche was granted 11,933 non-qualified stock options as compensation for board service.

Director Gloria F. Basse was granted 11,933 non-qualified stock options as compensation for board service.

Director Paul R. Wainman was granted 11,933 non-qualified stock options as compensation for board service.

Immurcell Corp director Bryan K. Gathagan acquired 10,000 stock options as compensation for board services.

Immurcell Corporation reports a grant of 10,000 stock options to Director Paul R. Wainman.

David Scott Tomsche, a Director at Immurcell Corporation, was granted 10,000 stock options on April 16, 2025.

Immurcel Corporation reports that Bobbi Jo Brockmann, VP of Sales and Marketing, was granted 5,000 incentive stock options.

Immurcell Corporation reports the grant of 10,000 stock options to Director Steven T. Rosgen.

Gloria F. Basse, a Director at Immuron Corp, was granted 10,000 non-qualified stock options with an exercise price of $5.49.

ImmuCell Director Michael F. Brigham exercised stock options and adjusted common stock holdings, resulting in a net change in beneficial ownership.

An amendment to a Form 4 filing reveals the corrected stock option grant for ImmuCell's President and CEO, Paul Francis Olivier te Boekhorst, tied to significant performance targets.

IMMUCELL Corporation's CFO, Timothy C. Fiori, was granted 120,000 stock options with an exercise price of $6.265, vesting over three years.

ImmuCell's VP of Sales and Marketing, Bobbi Jo Brockmann, was granted 100,000 stock options with a $6.265 exercise price, vesting over three years.

ImmuCell Corporation's President and CEO, Paul Francis Olivier te Boekhorst, was granted 110,000 performance-based stock options with a vesting condition tied to significant net operating income growth.

ImmuCell's President and CEO, Paul te Boekhorst, filed an amended Form 4 to correct details of recent common stock purchases, increasing his direct beneficial ownership to 9,738 shares.

ImmuCell's President and CEO, Paul Francis Olivier te Boekhorst, acquired additional common stock through open market purchases in early December 2025.

ImmuCell Director David Tomsche acquired 3,266 shares of common stock through direct and indirect ownership under a pre-arranged 10b5-1 plan.

ImmuCell's President and CEO, Paul Francis Olivier te Boekhorst, was granted 74,277 stock options with an exercise price of $6.10, vesting over three years.

ImmuCell Corporation Director Gloria F Basse exercised non-qualified stock options to acquire 3,530 shares of common stock through a net exercise transaction.

ImmuCell Corporation Director Bryan K. Gathagan has acquired 1,000 shares of the company's common stock at a price of $6.32 per share, as reported in a recent SEC Form 4 filing.

Timothy C. Fiori, CFO of ImmuCell Corp, reports the acquisition of 30,000 incentive stock options.

Director Paul R Wainman acquired 10,000 non-qualified stock options in ImmuCell Corp on September 20, 2024.

Gloria F. Basse, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options on September 20, 2024, at an exercise price of $3.60.

Director David Scott Tomsche acquired 10,000 non-qualified stock options in ImmuCell Corp on September 20, 2024, at an exercise price of $3.60.

Bryan K. Gathagan, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options on September 20, 2024.

Director Steven T. Rosgen acquired 10,000 non-qualified stock options in ImmuCell Corporation on September 20, 2024.

Director David Tomsche acquired 2,186 shares of ImmuCell Corp common stock at $3.55 per share on August 28, 2024.

Director David Scott Tomsche acquired 6,005 shares of ImmuCell Corp common stock at $3.55 per share on August 23, 2024.

Director David Tomsche purchased 10,000 shares of ImmuCell Corp common stock at $3.55 per share on August 22, 2024.